vs
Side-by-side financial comparison of Axon Enterprise (AXON) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $796.7M, roughly 1.4× Axon Enterprise). Axon Enterprise runs the higher net margin — 0.3% vs -127.8%, a 128.1% gap on every dollar of revenue. On growth, Axon Enterprise posted the faster year-over-year revenue change (38.9% vs -2.5%). Axon Enterprise produced more free cash flow last quarter ($155.4M vs $148.6M). Over the past eight quarters, Axon Enterprise's revenue compounded faster (31.5% CAGR vs 1.3%).
Axon Enterprise, Inc. is an American company based in Scottsdale, Arizona, that develops weapons and technology products for military, law enforcement, and civilians.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
AXON vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $796.7M | $1.1B |
| Net Profit | $2.7M | $-1.4B |
| Gross Margin | 57.9% | 32.6% |
| Operating Margin | -6.3% | -116.0% |
| Net Margin | 0.3% | -127.8% |
| Revenue YoY | 38.9% | -2.5% |
| Net Profit YoY | -98.0% | -3093.9% |
| EPS (diluted) | $0.02 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $796.7M | $1.1B | ||
| Q3 25 | $710.6M | $1.0B | ||
| Q2 25 | $668.5M | $1.1B | ||
| Q1 25 | $603.6M | $1.0B | ||
| Q4 24 | $573.4M | $1.1B | ||
| Q3 24 | $544.3M | $1.1B | ||
| Q2 24 | $504.1M | $1.1B | ||
| Q1 24 | $460.7M | $1.1B |
| Q4 25 | $2.7M | $-1.4B | ||
| Q3 25 | $-2.2M | $7.5M | ||
| Q2 25 | $36.1M | $-8.4M | ||
| Q1 25 | $88.0M | $-6.4M | ||
| Q4 24 | $136.0M | $-44.4M | ||
| Q3 24 | $67.0M | $-21.0M | ||
| Q2 24 | $40.8M | $-108.4M | ||
| Q1 24 | $133.2M | $2.0M |
| Q4 25 | 57.9% | 32.6% | ||
| Q3 25 | 60.1% | 36.1% | ||
| Q2 25 | 60.4% | 34.4% | ||
| Q1 25 | 60.6% | 37.6% | ||
| Q4 24 | 60.5% | 33.9% | ||
| Q3 24 | 60.8% | 37.2% | ||
| Q2 24 | 60.3% | 37.0% | ||
| Q1 24 | 56.4% | 33.1% |
| Q4 25 | -6.3% | -116.0% | ||
| Q3 25 | -0.3% | 7.0% | ||
| Q2 25 | -0.2% | 4.3% | ||
| Q1 25 | -1.5% | 4.5% | ||
| Q4 24 | -2.6% | 10.0% | ||
| Q3 24 | 4.4% | 7.4% | ||
| Q2 24 | 6.5% | -2.5% | ||
| Q1 24 | 3.5% | -5.1% |
| Q4 25 | 0.3% | -127.8% | ||
| Q3 25 | -0.3% | 0.7% | ||
| Q2 25 | 5.4% | -0.8% | ||
| Q1 25 | 14.6% | -0.6% | ||
| Q4 24 | 23.7% | -3.9% | ||
| Q3 24 | 12.3% | -1.9% | ||
| Q2 24 | 8.1% | -10.2% | ||
| Q1 24 | 28.9% | 0.2% |
| Q4 25 | $0.02 | $-10.23 | ||
| Q3 25 | $-0.03 | $0.05 | ||
| Q2 25 | $0.44 | $-0.06 | ||
| Q1 25 | $1.08 | $-0.05 | ||
| Q4 24 | $1.68 | $-0.32 | ||
| Q3 24 | $0.86 | $-0.15 | ||
| Q2 24 | $0.53 | $-0.79 | ||
| Q1 24 | $1.73 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | — |
| Total DebtLower is stronger | $1.8B | — |
| Stockholders' EquityBook value | $3.2B | $2.9B |
| Total Assets | $7.0B | $8.5B |
| Debt / EquityLower = less leverage | 0.56× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | — | ||
| Q3 25 | $2.4B | $432.1M | ||
| Q2 25 | $2.1B | $454.2M | ||
| Q1 25 | $2.2B | $409.9M | ||
| Q4 24 | $788.1M | $558.8M | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $968.9M | $542.8M | ||
| Q1 24 | $964.1M | $658.5M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $680.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.2B | $2.9B | ||
| Q3 25 | $3.0B | $4.4B | ||
| Q2 25 | $2.7B | $4.5B | ||
| Q1 25 | $2.6B | $4.4B | ||
| Q4 24 | $2.3B | $4.3B | ||
| Q3 24 | $2.1B | $4.6B | ||
| Q2 24 | $1.9B | $4.5B | ||
| Q1 24 | $1.8B | $4.7B |
| Q4 25 | $7.0B | $8.5B | ||
| Q3 25 | $6.7B | $10.1B | ||
| Q2 25 | $6.2B | $10.1B | ||
| Q1 25 | $6.1B | $9.8B | ||
| Q4 24 | $4.5B | $9.6B | ||
| Q3 24 | $4.0B | $11.2B | ||
| Q2 24 | $3.7B | $10.4B | ||
| Q1 24 | $3.6B | $10.6B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $217.2M | $175.4M |
| Free Cash FlowOCF − Capex | $155.4M | $148.6M |
| FCF MarginFCF / Revenue | 19.5% | 13.4% |
| Capex IntensityCapex / Revenue | 7.8% | 2.4% |
| Cash ConversionOCF / Net Profit | 79.14× | — |
| TTM Free Cash FlowTrailing 4 quarters | $75.1M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.2M | $175.4M | ||
| Q3 25 | $60.0M | $51.7M | ||
| Q2 25 | $-91.7M | $75.9M | ||
| Q1 25 | $25.8M | $-64.5M | ||
| Q4 24 | $250.2M | $312.6M | ||
| Q3 24 | $91.3M | $42.2M | ||
| Q2 24 | $82.8M | $9.5M | ||
| Q1 24 | $-15.9M | $-1.4M |
| Q4 25 | $155.4M | $148.6M | ||
| Q3 25 | $33.4M | $29.8M | ||
| Q2 25 | $-114.7M | $56.7M | ||
| Q1 25 | $932.0K | $-90.0M | ||
| Q4 24 | $225.4M | $274.9M | ||
| Q3 24 | $64.8M | $15.1M | ||
| Q2 24 | $71.4M | $-18.9M | ||
| Q1 24 | $-32.1M | $-26.5M |
| Q4 25 | 19.5% | 13.4% | ||
| Q3 25 | 4.7% | 2.9% | ||
| Q2 25 | -17.2% | 5.4% | ||
| Q1 25 | 0.2% | -8.6% | ||
| Q4 24 | 39.3% | 24.2% | ||
| Q3 24 | 11.9% | 1.4% | ||
| Q2 24 | 14.2% | -1.8% | ||
| Q1 24 | -7.0% | -2.4% |
| Q4 25 | 7.8% | 2.4% | ||
| Q3 25 | 3.7% | 2.1% | ||
| Q2 25 | 3.4% | 1.8% | ||
| Q1 25 | 4.1% | 2.4% | ||
| Q4 24 | 4.3% | 3.3% | ||
| Q3 24 | 4.9% | 2.5% | ||
| Q2 24 | 2.2% | 2.7% | ||
| Q1 24 | 3.5% | 2.3% |
| Q4 25 | 79.14× | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | -2.54× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 2.03× | — | ||
| Q1 24 | -0.12× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXON
| Software And Sensors Segment | $342.5M | 43% |
| TASER Devices Professional | $264.2M | 33% |
| Personal Sensors | $109.1M | 14% |
| Platform Solutions | $80.9M | 10% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
